問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Infectious Disease

更新時間:2024-06-03

詹明澄Chan, Ming -Cheng
  • Principal Investigator
  • Clinical Trial Experience (year)
  • mingcheng.chan@gmail.com

篩選

List

57Cases

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.
  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2023-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

Terminated1Sites

2005-12-01 - 2007-12-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-05-01 - 2023-05-17

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

2020-09-15 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2023-10-01 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-06-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2022-12-15 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2021-03-01 - 2023-07-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites